Our study sheds light on the IDH3β-lactate-PAX6-IDH3β positive feedback mechanism that underlies metabolic disorders, emphasizing the modulating potential of IDH3β as a new molecular target for AD therapy. This evidence concerns the gene IDH3B and Other metabolic disease.